Early & Late-Stage Venture Capital

With over 30 years of experience investing in novel life science technologies, we understand how challenging it can be to turn a great idea into a great company.

We are comfortable evaluating and taking significant scientific risks. Our team and network of advisors includes a number of former executives with first-hand experience of these challenges, who are available to provide support and advice when it is needed.

We also understand that building a successful company takes time and patience. Our team is committed to building real value over the long-term.

38product approvals
52M&A / exits
40+technical experts
65IPOs

"The business acumen and scientific insight provided by multiple members of the Abingworth team is invaluable to a young company like IFM. We are fortunate to be working with them as we grow and develop the company."

Gary Glick, CEO of IFM Therapeutics

"I feel fortunate to have Abingworth as an investor in Wilson Therapeutics. Their in-depth knowledge of drug development in combination with being very well connected in the life science industry adds great value to our company."

Jonas Hansson, CEO of Wilson Therapeutics

"Abingworth was the first institutional investor to reach out directly to VenatoRx, even before we were looking to fund-raise. They have excellent knowledge of the infectious disease domain space and had clearly done their homework. We enjoy a strong collaborative relationship that adds significant value to the company."

Christopher Burns, CEO of VenatoRx

"Working with Abingworth to build CRISPR Therapeutics is a pleasure. They are incredibly supportive in shaping the company, which aims to lead the highly dynamic and competitive environment of gene editing."

Rodger Novak, Chairman of CRISPR Therapeutics

"Abingworth is an excellent investor for GammaDelta Therapeutics. Using strong scientific expertise and astute business sense they drove the seed investment with King’s College and the Crick institute and then our highly productive collaboration with Takeda. High quality science and ethical behaviour form the foundation of day-by-day activities at Abingworth and it is extremely reassuring to have such partners."

Paolo Paoletti, CEO of GammaDelta Therapeutics